Power your clinical decisions or research with precision genomics kitted solutions that enable personalized cancer care for all.
Partner with PGDx to access proven thought leadership, regulatory expertise, and proprietary tools to advance your oncology drug development pipeline.
We create clarity for patients and their clinicians by removing barriers to precision oncology testing to make timely, personalized treatments a reality for all.
Explore our collection of educational resources, publications, and more
Researchers all around the world are using PGDx elio tissue complete. Here are some of the breakthroughs that have been made possible.
Derazantinib and Atezolizumab in Patients With Urothelial Cancer (FIDES-02).
Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma (FIDES-03).
A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475 – 495/KEYNOTE-495).
Prevention of recurrent disease by additional chemotherapy in patients with detectable circulating tumor DNA in the blood after surgery for stage II (lymph nodes unaffected) colon cancer.